Caplin Point Laboratories Ltd. (CAPLIPOINT) fundamentals
Caplin Point Laboratories Ltd. is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as CAPLIPOINT (ISIN INE475E01026). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Caplin Point Laboratories Ltd. does
Caplin Point Laboratories Limited is an India-based pharmaceutical company with a business model catering predominantly to emerging markets of Latin America and Africa. The Company has also entered regulated markets such as the United States through its Subsidiary, Caplin Steriles Limited. The Company's operations include research & development and manufacturing of finished formulations, active pharmaceutical ingredients (APIs), clinical research, front-end generic presence in Latin America, brand marketing in Francophone Africa and a USFDA/EU-GMP approved injectable facility. In the Regulated Markets, its products include liquid & lyophilized vials, pre-filled syringes, three-pc ophthalmic droppers and pre-mix bags. In the Emerging Markets, its products include tablets, dry syrups - bottles, soft gels, capsules, suppositories, liquid syrups - bottles, liquid injectables in ampoules & vials, lyophilized vials, prefilled syringes (PFS), and emulsion injection in ampoules & vials.
Valuation and market data
| Last close | ₹2273.90 |
|---|---|
| Market capitalisation | ₹17,513 crore |
| Enterprise value | ₹17,448 crore |
| P/E (TTM) | 26.95 |
| Price to book | 4.82 |
| Price to sales (TTM) | 4.41 |
| Book value per share | ₹471.42 |
| Dividend yield | 35.18% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Mon Jun 23 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹934 crore | ₹508 crore | ₹397 crore | 52.17 |
| Mar 2025 | ₹887 crore | ₹442 crore | ₹339 crore | 44.67 |
| Mar 2024 | ₹731 crore | ₹366 crore | ₹284 crore | 37.36 |
| Mar 2023 | ₹628 crore | ₹293 crore | ₹234 crore | 30.89 |
| Mar 2022 | ₹585 crore | ₹250 crore | ₹188 crore | 24.82 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Sep 2026:
| Promoters | 70.6% |
|---|---|
| Foreign institutions (FII) | 5.7% |
| Mutual funds | 1.6% |
| Other domestic institutions | 0.6% |
| Retail and others | 21.5% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.